Bruce Gershenhorn, DO
Hematology & Oncology · Downers Grove, ILNPI 1588796478
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,173 of the $23,363 with a category attached, or 77.8%. AstraZeneca accounts for 76.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $12,763 and has fallen 99.1% since, to $113 in 2025.
Across 259 payments — averaging $90.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Jazz Pharmaceuticals Inc.$1K
- E.r. Squibb & Sons, L.L.C.$537
- Merck$470
- Pfizer$468
- Genentech USA, Inc.$386
- plus $2K from 25 others
Across 11 payments — averaging $4679.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$32K
- E.r. Squibb & Sons, L.L.C.$8K
- Merck$8K
- Spectrum Pharmaceuticals Inc.$4K
What the payments were for
- Consulting fees$18,17378%
- Travel & lodging$4482%
- Food & beverage$4,70120%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $17,803 |
| Jazz Pharmaceuticals Inc. | 1 | $1,313 |
| E.r. Squibb & Sons, L.L.C. | 22 | $537 |
| Merck | 28 | $470 |
| Pfizer | 32 | $468 |
| Genentech USA, Inc. | 21 | $386 |
| Novartis | 25 | $383 |
| Amgen | 11 | $213 |
| Johnson & Johnson(2 entities) | 5 | $168 |
| Bayer | 7 | $151 |
| Lilly USA, LLC | 7 | $148 |
| Astellas Pharma US Inc | 3 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $146 |
| Taiho Oncology, Inc. | 7 | $144 |
| EMD Serono, Inc. | 12 | $135 |
| Boehringer Ingelheim | 7 | $118 |
| Exelixis Inc. | 4 | $83 |
| Ipsen Biopharmaceuticals, Inc | 4 | $81 |
| Bristol Myers Squibb | 4 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
| Gilead | 3 | $62 |
| Immunogen, Inc. | 1 | $45 |
| G1 Therapeutics, Inc. | 2 | $41 |
| Array Biopharma Inc | 3 | $39 |
| Cumberland Pharmaceuticals, Inc. | 2 | $30 |
| Eisai Inc. | 1 | $24 |
| Seagen Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,363 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 28 | $426,750 |
| EliquisApixaban | 95 | $64,231 |
| XareltoRivaroxaban | 35 | $33,654 |
| Dexamethasone | 14 | $553 |
| Duloxetine Hcl | 13 | $504 |
| Levothyroxine Sodium | 14 | $343 |
| Prochlorperazine Maleate | 42 | $297 |
| Acyclovir | 12 | $222 |
| Ondansetron OdtOndansetron | 12 | $201 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $176 |
| Ondansetron Hcl | 14 | $158 |
| Anastrozole | 11 | $135 |
| Prednisone | 23 | $118 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $88 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $17,803 | $426,75028 claims |
| PfizerEliquis | $468 | $64,23195 claims |
| Johnson & JohnsonXarelto | $168 | $33,65435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Downers Grove
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.